期刊文献+

EBV编码潜伏膜蛋白2A抗原表位的串联表达及其免疫原性分析 被引量:2

Preparation and immunogenicity characteristics analysis of a epitope fusion protein of Epstein-Bar virus encoded latent membrane protein 2A
下载PDF
导出
摘要 目的:制备具有免疫原性的EB病毒潜伏膜蛋白2A(latent membrane protein 2A,LMP2A)的表位串联蛋白并分析其免疫学特性。方法:用DNAstar软件分析LMP2A的抗原表位,将预测的免疫原性较强的两个表位通过基因合成串联在一起,克隆到原核表达载体pET28a中,经大肠杆菌BL21表达并纯化。制备的含LMP2A表位重组蛋白经SDS-PAGE、Western blot鉴定后,免疫小鼠制备多克隆抗体,以ELISA检测抗体的效价,免疫组织化学法检测该抗体对天然LMP2A的特异性。结果:通过原核表达与纯化,获得高纯度的表位融合蛋白,经小鼠免疫并制备效价高且特异性的小鼠抗LMP2A的多克隆抗体,该抗体可用于ELISA和免疫组织化学分析。结论:本研究制备的表位融合蛋白,具有天然抗原的免疫原性,可制备能特异性识别天然LMP2A分子的多克隆抗体,为利用表位融合蛋白筛选全人源基因工程抗体奠定了基础。 Objective:To prepare a immunogenic epitope tandem of latent membrane protein 2A (LMP2A) of Epstein-Barr virus and analyze its characteristics of immunology. Methods:LMP2A epitopes were analyzed by using DNAstar software,and two immunogenic epitopes were selected due to stronger immunogenicity. The genes of these two epitopes were integrated through gene synthesis, and then cloned into prokaryotie expression vector pET28a. The recombinant epitopes were expressed and purified by E.coli BL21,and then the protein was utilized to immunize mouse to prepare anti-epitope fusion protein polyclonal antibody after the analysis of SDS-PAGE and Western blot assay. The titer of the antibody was assessed by ELISA and the immunobistochemical experiment was performed to test the specificity of the polyclonal antibody for natural LAMP2A. Results:Through prokaryotic expression and purification, high purity fusion protein was obtained. By mouse immunization, anti-LMP2A polyclonal antibody of high titer and specificity was prepared, which can be applied to ELISA and immunohistochemical analysis. Conclusion:An epitope fusion protein,which shares the natural antigen immunogenicity,can be used to prepare the polyclonal antibody specific for LMP2A. This study has laid a solid foundation for screening whole humanized genetic engineering antibody by epitope fusion protein.
出处 《南京医科大学学报(自然科学版)》 CAS CSCD 北大核心 2013年第5期593-597,共5页 Journal of Nanjing Medical University(Natural Sciences)
基金 南京医科大学科技发展基金重点项目(NY2005 D2D13) 江苏省自然科学基金(BK2008481) 江苏省科技厅社会发展支撑计划项目(BE2009152)
关键词 鼻咽癌 EB病毒 潜伏膜蛋白2A 多克隆抗体 重组基因 nasopharyngeal carcinoma Epstein-Barr virus latent membrane protein 2A polyclonal antibody recombinant gene
  • 相关文献

参考文献13

  • 1王雪峰,付宁,曹建国.鼻咽癌的临床进展[J].江西中医药,2010,41(3):78-80. 被引量:5
  • 2Lin JC,Chemg JM,Lin HJ,et al. Amino acid changes infunctional domains of latent membrane protein 1 of Ep-stein-Barr virus in nasopharyngeal carcinoma of southernChina and Taiwan : prevalence of an HLA A2-restricted ’epitope-loss variant’ [J]. J Gen Virol,2004,85(Pt 7):2023-2034.
  • 3徐丽娜,郑军,李姣,石磊,范松青.高通量组织微阵列研究Wnt5a和LMP1在鼻咽癌癌变中的作用[J].中南大学学报(医学版),2012,37(9):865-870. 被引量:3
  • 4Dawson CW,Port RJ, Young LS. The role of the EBV-en-coded latent membrane proteins LMP1 and LMP2 in thepathogenesis of nasopharyngeal carcinoma (NPC) [J].Semin Cancer Biol,2012,22(2) : 144-153.
  • 5Pegtel DM,Subramanian A,Sheen TS,et al. Epstein-Barr-virus-encoded LMP2A induces primary epithelial cell mi-gration and invasion : possible role in nasopharyngeal car-cinoma metastasis[J]. J Virol,2005,79 (24) : 15430-15442.
  • 6Kong QL,Hu U,Cao JY,et al. Epstein-Barr virus-encod-ed LMP2A induces an epithelial-mesenchymal transitionand increases the number of side population stem-likecancer cells in nasopharyngeal carcinoma[J]. PLoS Pathog,2010,6 (6 ) : e 1000940.
  • 7温爽,刘媛,王家伟,谢雅晶,刘贤进,梁建生.抗伊维菌素scFv蛋白质的变复性及纯化[J].江苏农业学报,2011,27(3):682-684. 被引量:1
  • 8Brooks L,Yao QY,Rickinson AB,et al. Epstein-Barr viruslatent gene transcription in nasopharyngeal carcinomacells : coexpression of EBNA1, LMP1, and LMP2 transcripts[J]. J Virol, 1992,66(5) :2689-2697.
  • 9Niedobitek G, Young LS,Sam CK,et al. Expression of Ep-stein-Barr virus genes and of lymphocyte activationmolecules in undifferentiated nasopharyngeal carcinomas[J]. Am J Pathol,1992,140(4) :879-887.
  • 10Heussinger N,Buttner M,0tt G,et al. Expression of theEpstein-Barr virus (EBV)-encoded latent membrane pro-tein 2A(LMP2A) in EBV-associated nasopharyngeal car-cinoma[J]. J Pathol,2004,203(2) :696-699.

二级参考文献22

  • 1王晖,彭莉,涂青松,胡炳强.鼻咽癌组织Bcl-2和Bax蛋白表达及其临床意义[J].中国医师杂志,2005,7(4):556-557. 被引量:4
  • 2梁海慧,张月飞.抑癌基因p16与鼻咽癌相关性的研究进展[J].广东医学,2007,28(7):1194-1196. 被引量:3
  • 3Wakisaka N,Wen QH,Yoshizaki T,et al.Associationof vascular endothelial growth factor expression withangiogenesis and lymph node metastasis in nasopharyngealcarcinom[J].Laryngoscope,1999,109(5):810-814.
  • 4CookGJ.Oncologicalmolecularimaging:Nuclearmedicinetechniques[J].BrJRadiol,2003,76(suppl):152-158.
  • 5Levendag PC,Lagerwaard FJ,Noever I,et a.l Role of endocavitarybrachytherapywith orwithout chemotherapy in cancer of the naso-pharynx[J].Int J RadiatOncol Biol Phys,2002,52(3):755-768.
  • 6Jereczek-Fossa BA,Morn A,DeBraud F,et a.l Hyperfractionatedradiotherapy in locally advanced nasopharyngeal cancer:analysis of43 consecutive patients[J].StrahlentherOnko,l 2004,180(7):425-433.
  • 7Baujat B,AudryH,Bourhis J,et a.l Chemotherapy in locally ad-vanced nasopharyngeal carcinoma:an individual patient data meta-analysis of eight randomized trial and 1753 patients[J].Int JRadiatOncolBiolPhys,2006,64(1):47-56.
  • 8齐卫卫,胡国清,汪瑞.鼻咽癌中survivin和Bcl-2的表达及其与预后相关性的研究[G].2006第四届中国肿瘤学大会论文集,59.
  • 9MISAWA S, KUMAGAI I, Refolding oftherapeutic proteins pro- duced in Escherichia coil as inclusion bodies [ J ]. Biopolymers, 1999, 51:297-307.
  • 10RUDOLPH H, BOHM G, LIME H, et al. Folding proteins [M]. New York:IRL Press, 1997.

共引文献6

同被引文献28

  • 1韦正波,黄光武,温文胜,张哲,谢莹.鼻咽癌患者外周血树突状细胞体外扩增及生物学特性的研究[J].临床耳鼻咽喉科杂志,2005,19(23):1068-1071. 被引量:4
  • 2匡志鹏,梁安民.CIK细胞联合树突状细胞治疗恶性肿瘤的研究进展[J].现代肿瘤医学,2006,14(2):240-242. 被引量:22
  • 3许文嵘,姚堃,陈云,尹全章,徐建,周锋.EB病毒潜伏膜蛋白2A胞外区重组基因在大肠杆菌中的表达及其在血清学检测中的应用[J].南京医科大学学报(自然科学版),2007,27(3):209-212. 被引量:1
  • 4Yashin DV,Sashchenko LP,Kabanova OD,et al. The CD8^+ population of LAK cells can lyse both HLA-positive and HLA-negative cancer cell lines[J]. Dokl Biol Sci, 2009,426 : 296-297.
  • 5Sebastian M,Passlick B, Friccius-Quecke H,et al. Treat- ment of non-small cell lung cancer patients with the tri- functional monoclonal antibody catumaxomab (anti-Ep- CAM x anti-CD3):a phase I study[J]. Cancer Immunol Immunother, 2007,56(10) : 1637-1644.
  • 6Yao Y,Chen L,Wei W,et al. Tumor cell-derived exo- some-targeted dendritic cells stimulate stronger CD8^+ CTL responses and antitumor immunities[J]. Biochem Biophys Res Commun, 2013,436 ( 1 ) : 60-65.
  • 7Haque T,Wilkie GM,Jones MM,et al. Allogeneic cyto- toxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease:results of a phase 2 multi- center clinical trial[J]. Blood, 2007,110(4) : 1123-1131.
  • 8Icheva V, Kayser S,Wolff D,et al. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoprolif- erative disorders after allogeneic stem-cell transplantation [J]. J Clin Oncol,2013,31 (1) : 39-48.
  • 9Basso S,Zecca M,Merli P,et al. T cell therapy for na- sopharyngeal carcinoma [ J ]. J Cancer, 2011,2 : 341-346.
  • 10Pan J,Zhang Q,Zhou J,et al. Recombinant adeno-associ- ated virus encoding Epstein-Barr virus latent membrane proteins fused with heat shock protein as a potential vac- cine for nasopharyngeal carcinoma[J]. Mol Cancer Ther, 2009,8(9) :2754-2761.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部